AR035892A1 - Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos - Google Patents
Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentosInfo
- Publication number
- AR035892A1 AR035892A1 ARP020101739A ARP020101739A AR035892A1 AR 035892 A1 AR035892 A1 AR 035892A1 AR P020101739 A ARP020101739 A AR P020101739A AR P020101739 A ARP020101739 A AR P020101739A AR 035892 A1 AR035892 A1 AR 035892A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparation
- compounds
- formula
- pharmaceutical compositions
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Abstract
Derivados de oxazol de fórmula (1) en donde: R1 es arilo o heteroarilo; R2, R3, R4 y R6 independientemente el uno del otro son hidrógeno, hidroxi, alquenilo inferior, halógeno, alquilo inferior o alcoxi inferior, en donde al menos uno de R2, R3, R4 y R6 no es hidrógeno, o R3 y R4 están unidos el uno al otro para formar un anillo junto con los átomos de carbono a los que están unidos, y R3 y R4 juntos son -CH=CH-S-, -S-CH=CH-, -Ch=CH-O-, -O-CH=CH-, -CH=CH-CH=CH-, -(CH2)3-5-, -O-(CH2)2-3- ó -(CH2)2-3-O- y, donde R2 y R6 son como se ha definido antes; R5 es alcoxi inferior, alqueniloxi inferior, un resto de fórmula (2) o un resto de fórmula (3); R7, R8 y R9 son independientemente hidrógeno o alquilo inferior; R10 es arilo; n es 1, 2 ó 3; en donde el enlace entre el átomo de Ca y el átomo de Cb es un enlace de átomos de carbono doble o sencillo; y sales farmacéuticamente aceptables y ésteres de los mismos. También se dan a conocer: un proceso para su preparación, composiciones farmacéuticas que los comprenden, y el uso de dichos compuestos en la preparación de medicamentos. Dichos compuestos son útiles en el tratamiento y/o profilaxis de enfermedades que están moduladas por agonistas PPARalfa y/o PPARgamma, tales como diabetes.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01111745 | 2001-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035892A1 true AR035892A1 (es) | 2004-07-21 |
Family
ID=8177436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101739A AR035892A1 (es) | 2001-05-15 | 2002-05-13 | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos |
Country Status (39)
Country | Link |
---|---|
US (1) | US6642389B2 (es) |
EP (1) | EP1392295B1 (es) |
JP (2) | JP4330883B2 (es) |
KR (1) | KR100654516B1 (es) |
CN (1) | CN100356917C (es) |
AR (1) | AR035892A1 (es) |
AT (1) | ATE327753T1 (es) |
AU (1) | AU2002342244B2 (es) |
BG (1) | BG66316B1 (es) |
BR (1) | BRPI0209821B1 (es) |
CA (1) | CA2445145C (es) |
CY (1) | CY1105160T1 (es) |
CZ (1) | CZ20033037A3 (es) |
DE (1) | DE60211891T2 (es) |
DK (1) | DK1392295T3 (es) |
EC (1) | ECSP034848A (es) |
EG (1) | EG25755A (es) |
ES (1) | ES2264482T3 (es) |
GT (1) | GT200200085A (es) |
HK (1) | HK1067534A1 (es) |
HR (1) | HRP20030889B1 (es) |
HU (1) | HU230224B1 (es) |
IL (2) | IL158589A0 (es) |
JO (1) | JO2282B1 (es) |
MA (1) | MA27025A1 (es) |
ME (1) | ME01310B (es) |
MX (1) | MXPA03010435A (es) |
MY (1) | MY136761A (es) |
NO (1) | NO333833B1 (es) |
NZ (1) | NZ529033A (es) |
PA (1) | PA8544901A1 (es) |
PE (1) | PE20021152A1 (es) |
PL (1) | PL208074B1 (es) |
PT (1) | PT1392295E (es) |
RU (1) | RU2278859C2 (es) |
SI (1) | SI1392295T1 (es) |
SK (1) | SK287842B6 (es) |
WO (1) | WO2002092084A1 (es) |
ZA (1) | ZA200308538B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2259361C2 (ru) * | 2000-05-26 | 2005-08-27 | Ниппон Синяку Ко., Лтд. | Профилактическое или терапевтическое средство и фармацевтическая композиция, содержащая гетероциклическое соединение |
DK1392295T3 (da) * | 2001-05-15 | 2006-10-02 | Hoffmann La Roche | Carboxylsyre-substituerede oxazol-derivater til anvendelse som PPAR-alpha og -gamma-aktivatorer i behandlingen af diabetes |
US7456184B2 (en) * | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7655658B2 (en) * | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7732451B2 (en) * | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
EP1480642B1 (en) | 2002-02-25 | 2008-11-26 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
CN100475810C (zh) * | 2002-08-30 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 作为PPARα和PPARγ激动剂的新型2-芳基噻唑化合物 |
TWI343915B (en) | 2002-10-07 | 2011-06-21 | Hoffmann La Roche | Chirale ppar agonists |
ATE420079T1 (de) * | 2002-11-15 | 2009-01-15 | Cadila Healthcare Ltd | Substituierte aralkyl verbindungen |
ATE405560T1 (de) * | 2002-11-25 | 2008-09-15 | Hoffmann La Roche | Indolderivaten |
US7268157B2 (en) * | 2002-11-26 | 2007-09-11 | Shenzhen Chipscreen Biosciences, Ltd. | Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity |
FR2849849B1 (fr) * | 2003-01-13 | 2006-08-04 | Merck Sante Sas | Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
US7968548B2 (en) * | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7262303B2 (en) * | 2003-09-29 | 2007-08-28 | Hoffman-La Roche Inc. | Process for the production of chiral propionic acid derivatives |
KR20080042188A (ko) | 2003-11-05 | 2008-05-14 | 에프. 호프만-라 로슈 아게 | Ppar 작용제로서 페닐 유도체 |
JP2007509998A (ja) * | 2003-11-05 | 2007-04-19 | エフ.ホフマン−ラ ロシュ アーゲー | Ppar活性化剤としてのベンズ環付加された化合物 |
WO2005056536A1 (en) * | 2003-12-10 | 2005-06-23 | Ranbaxy Laboratories Limited | Antidiabetic agents which exhibit activity against ppar |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
CN1950365A (zh) | 2004-05-03 | 2007-04-18 | 霍夫曼-拉罗奇有限公司 | 作为肝脏-x-受体调节剂的吲哚基衍生物 |
CN100436430C (zh) * | 2004-05-24 | 2008-11-26 | 北京摩力克科技有限公司 | 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物 |
CN100344618C (zh) * | 2004-05-24 | 2007-10-24 | 北京摩力克科技有限公司 | 作为hPPARα和hPPARγ激动剂的N-芳丙烯酰基取代的酪氨酸衍生物 |
WO2006108491A1 (en) * | 2005-04-11 | 2006-10-19 | Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg | Improved process for preparing oxazole nitriles |
US20060241073A1 (en) * | 2005-04-20 | 2006-10-26 | Wanders Ronaldus J A | Means and methods for counteracting fatty acid accumulation |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
KR100847780B1 (ko) * | 2006-10-26 | 2008-07-23 | 재단법인서울대학교산학협력재단 | 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제 |
JP2010520873A (ja) * | 2007-03-07 | 2010-06-17 | ドン・ア・ファーム・カンパニー・リミテッド | ペルオキシソーム増殖因子活性化γ受容体調節因子としての新規フェニルプロピオン酸誘導体、その方法およびそれを含む医薬組成物 |
DK2100604T3 (da) * | 2008-03-10 | 2012-07-23 | Nestec Sa | Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser |
EP2291078A4 (en) * | 2008-05-15 | 2011-08-24 | Merck Sharp & Dohme | OXAZOLBENZIMIDAZOLDERIVATE |
CN102265279B (zh) | 2008-12-23 | 2019-08-23 | 霍夫曼-拉罗奇有限公司 | 用于慢性病患者的诊断或者治疗支持的结构化测试方法及其设备 |
SG173058A1 (en) * | 2009-01-23 | 2011-08-29 | Hoffmann La Roche | Pharmaceutical composition comprising aleglitazar |
CN101805337B (zh) * | 2009-02-13 | 2012-05-23 | 天津药物研究院 | 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途 |
US8450496B2 (en) * | 2009-03-24 | 2013-05-28 | Hoffman-La Roche Inc. | Process for the preparation of propionic acid derivatives |
SG182259A1 (en) | 2009-12-07 | 2012-08-30 | Hoffmann La Roche | Process for the preparation of propionic acid derivatives |
CN102351852B (zh) * | 2011-08-23 | 2014-06-18 | 上海交通大学 | 苯并呋喃类化合物及其制备方法、用途 |
WO2013181384A1 (en) | 2012-05-31 | 2013-12-05 | Ratiopharm Gmbh | Solid state forms of aleglitazar sodium |
CN104619689B (zh) * | 2012-09-12 | 2017-08-08 | 霍夫曼-拉罗奇有限公司 | (S)‑2‑甲氧基‑3‑{4‑[2‑(5‑甲基‑2‑苯基‑噁唑‑4‑基)‑乙氧基]‑苯并[b]噻吩‑7‑基}‑丙酸的固体形式及其盐的固体形式 |
EP3402482A1 (en) | 2015-11-18 | 2018-11-21 | H. Hoffnabb-La Roche Ag | Aleglitazar for the treatment of diabetic kidney disease |
US20190350955A1 (en) | 2016-06-30 | 2019-11-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Methods and pharmaceutical compositions for the treatment of cardiomyopathies |
WO2020156683A1 (en) | 2019-02-01 | 2020-08-06 | F. Hoffmann-La Roche Ag | Aleglitazar for use in the treatment or prevention of major adverse cardiac events |
WO2020201263A1 (en) | 2019-04-01 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling |
CA3227149A1 (en) * | 2021-08-13 | 2023-02-16 | Alebund Pharmaceuticals (Hong Kong) Limited | Deuterated compounds |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4011326A (en) | 1975-07-29 | 1977-03-08 | Merck & Co., Inc. | 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents |
US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
PL174610B1 (pl) | 1992-07-03 | 1998-08-31 | Smithkline Beecham Plc | Nowe związki heterocykliczne |
GB9225386D0 (en) | 1992-12-04 | 1993-01-27 | Smithkline Beecham Plc | Novel compounds |
DE4317320A1 (de) | 1993-05-25 | 1994-12-01 | Boehringer Mannheim Gmbh | Neue Thiazolidindione und diese enthaltende Arzneimittel |
GB9326171D0 (en) | 1993-12-22 | 1994-02-23 | Smithkline Beecham Plc | Novel compounds |
GB9600464D0 (en) | 1996-01-09 | 1996-03-13 | Smithkline Beecham Plc | Novel method |
GB9604242D0 (en) * | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
KR100499106B1 (ko) | 1996-12-10 | 2005-07-01 | 브리스톨-마이어즈 스퀴브 컴페니 | 벤조디옥솔, 벤조퓨란, 디히드로벤조퓨란, 및 벤조디옥산 멜라토닌 작용제 |
DE19711616A1 (de) | 1997-03-20 | 1998-09-24 | Boehringer Mannheim Gmbh | Verbessertes Verfahren zur Herstellung von Thiazolidindionen |
US6121397A (en) | 1997-07-14 | 2000-09-19 | Xerox Corporation | Polymerization processes using oligomeric compound, monomer and surfactant |
HN1998000118A (es) | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
EP0903343B1 (en) | 1997-09-19 | 2003-05-28 | SSP Co., Ltd. | Alpha-Substituted phenylpropionic acid derivative and medicine containing the same |
ATE286032T1 (de) | 1998-04-23 | 2005-01-15 | Reddys Lab Ltd Dr | Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen |
GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
DK1078923T3 (da) | 1999-08-02 | 2006-07-10 | Hoffmann La Roche | Fremgangsmåde til fremstilling af benzothiophenderivater |
KR20030027054A (ko) * | 2000-08-23 | 2003-04-03 | 일라이 릴리 앤드 캄파니 | 옥사졸릴-아릴프로피온산 유도체 및 ppar효능제로서의 그의 용도 |
DK1392295T3 (da) * | 2001-05-15 | 2006-10-02 | Hoffmann La Roche | Carboxylsyre-substituerede oxazol-derivater til anvendelse som PPAR-alpha og -gamma-aktivatorer i behandlingen af diabetes |
-
2002
- 2002-05-06 DK DK02742955T patent/DK1392295T3/da active
- 2002-05-06 SI SI200230340T patent/SI1392295T1/sl unknown
- 2002-05-06 ME MEP-2008-775A patent/ME01310B/me unknown
- 2002-05-06 KR KR1020037014816A patent/KR100654516B1/ko active IP Right Grant
- 2002-05-06 EP EP02742955A patent/EP1392295B1/en not_active Expired - Lifetime
- 2002-05-06 NZ NZ529033A patent/NZ529033A/en not_active IP Right Cessation
- 2002-05-06 MX MXPA03010435A patent/MXPA03010435A/es active IP Right Grant
- 2002-05-06 PT PT02742955T patent/PT1392295E/pt unknown
- 2002-05-06 PL PL367087A patent/PL208074B1/pl unknown
- 2002-05-06 AT AT02742955T patent/ATE327753T1/de active
- 2002-05-06 WO PCT/EP2002/004962 patent/WO2002092084A1/en active IP Right Grant
- 2002-05-06 CN CNB028100964A patent/CN100356917C/zh not_active Expired - Fee Related
- 2002-05-06 ES ES02742955T patent/ES2264482T3/es not_active Expired - Lifetime
- 2002-05-06 CA CA002445145A patent/CA2445145C/en not_active Expired - Fee Related
- 2002-05-06 SK SK1385-2003A patent/SK287842B6/sk not_active IP Right Cessation
- 2002-05-06 DE DE60211891T patent/DE60211891T2/de not_active Expired - Lifetime
- 2002-05-06 IL IL15858902A patent/IL158589A0/xx unknown
- 2002-05-06 RU RU2003134150/04A patent/RU2278859C2/ru not_active IP Right Cessation
- 2002-05-06 CZ CZ20033037A patent/CZ20033037A3/cs unknown
- 2002-05-06 HU HU0400992A patent/HU230224B1/hu not_active IP Right Cessation
- 2002-05-06 AU AU2002342244A patent/AU2002342244B2/en not_active Ceased
- 2002-05-06 BR BRPI0209821A patent/BRPI0209821B1/pt not_active IP Right Cessation
- 2002-05-06 JP JP2002589001A patent/JP4330883B2/ja not_active Expired - Fee Related
- 2002-05-09 US US10/142,567 patent/US6642389B2/en not_active Expired - Lifetime
- 2002-05-13 AR ARP020101739A patent/AR035892A1/es active IP Right Grant
- 2002-05-13 JO JO200242A patent/JO2282B1/en active
- 2002-05-13 MY MYPI20021726A patent/MY136761A/en unknown
- 2002-05-14 PE PE2002000399A patent/PE20021152A1/es active IP Right Grant
- 2002-05-14 PA PA20028544901A patent/PA8544901A1/es unknown
- 2002-05-14 GT GT200200085A patent/GT200200085A/es unknown
- 2002-05-14 EG EG2002050495A patent/EG25755A/xx active
-
2003
- 2003-10-23 IL IL158589A patent/IL158589A/en unknown
- 2003-10-31 ZA ZA2003/08538A patent/ZA200308538B/en unknown
- 2003-11-04 HR HR20030889A patent/HRP20030889B1/xx not_active IP Right Cessation
- 2003-11-13 EC EC2003004848A patent/ECSP034848A/es unknown
- 2003-11-14 BG BG108362A patent/BG66316B1/bg unknown
- 2003-11-14 NO NO20035086A patent/NO333833B1/no not_active IP Right Cessation
- 2003-11-14 MA MA27399A patent/MA27025A1/fr unknown
-
2004
- 2004-12-07 HK HK04109665A patent/HK1067534A1/xx not_active IP Right Cessation
-
2006
- 2006-08-22 CY CY20061101162T patent/CY1105160T1/el unknown
-
2009
- 2009-02-10 JP JP2009028181A patent/JP2009138011A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
AR038419A1 (es) | Derivados de piridina y quinolina | |
AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
SV2001000020A (es) | Derivados de quinolina-2-uno substituido de heteroarilo util como agente anti-canceroso ref.pc10198/82888/bb | |
UY26143A1 (es) | Derivados heterocíclicos útiles como agentes anticancerosos | |
AR041997A1 (es) | Derivados de oxaxol sustituidos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de la diabetes | |
AR068695A2 (es) | Uso de un compuesto de tiazol que comprende un derivado de tiazol para la fabricacion de un medicamento para la prevencion y el tratamiento de en-fermedades causadas por la produccion anormal de citocinas y/o la acele-racion de la adhesion de neutrofilos y/o la produccion anormal de tnf- alfa | |
AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AR035260A1 (es) | Derivados de piperidina amino sustituidas, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de medicamentos como inhibidores de la gama secretasa, y para el tratamiento de la enfermedad de alzheimer | |
AR016725A1 (es) | Compuestos derivados de isotiazol utiles como agentes anticancerosos, composiciones farmaceuticas, su uso en la preparacion de medicamentos y proceso para su preparacion | |
AR079260A1 (es) | Inhibidores de bencimidazol de la produccion de leucotrienos, un procedimiento para su preparacion, composiciones farmaceuticas que los comprenden y su empleo como medicamentos en el tratamiento de trastornos mediados por leucotrienos | |
SE9702799D0 (sv) | New compounds | |
PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
ECSP034672A (es) | Derivados de quinuclidina novedosos y composiciones medicinales que los contienen | |
AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
HUP0200248A2 (hu) | Pajzsmirigy-receptor ligandumként alkalmazható oxámsavszármazékok, azokat hatóanyagként tartalmazó gyógyszerkészítmények, valamint alkalmazásuk | |
NO20054264L (no) | Ikke-Nukleoside Revers Transkriptase-Inhibitorer I for behandling av HIV-medierte sydommer | |
CO5540385A2 (es) | Derivados quirales de acido oxazol arilpropionico, su metodo de sintesis ycomposiciones farmaceuticas que los contienen | |
AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
AR045859A1 (es) | Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos | |
AR041079A1 (es) | Derivados de 2-ariltiazol como agonistas de receptores activados proliferadores de peroxisomas alfa y gamma (ppar alfa y gamma) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |